Navellier & Associates Inc Biogen Inc. Transaction History
Navellier & Associates Inc
- $839 Million
- Q2 2024
A detailed history of Navellier & Associates Inc transactions in Biogen Inc. stock. As of the latest transaction made, Navellier & Associates Inc holds 2,164 shares of BIIB stock, worth $421,136. This represents 0.06% of its overall portfolio holdings.
Number of Shares
2,164
Previous 2,164
-0.0%
Holding current value
$421,136
Previous $466,000
7.51%
% of portfolio
0.06%
Previous 0.06%
Shares
1 transactions
Others Institutions Holding BIIB
# of Institutions
1,050Shares Held
128MCall Options Held
1.22MPut Options Held
1.4M-
Vanguard Group Inc Valley Forge, PA16.6MShares$3.23 Billion0.08% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$3.18 Billion2.78% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.83 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.1MShares$1.38 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.68MShares$1.11 Billion0.83% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $28B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...